|
|
Article: U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON[R] for Malignant Melanoma.
- Article from:
- Hepatitis Weekly
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Schering-Plough Corp. (NYSE:SGP) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON=AE (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy (see also Melanoma).
Schering-Plough will work closely with FDA to respond to outstanding concerns related to the PEGINTRON melanoma filing.
In early October, the FDA's Oncologic Drugs Advisory Committee recommended approval of PEGINTRON in this indication by a vote of 6 to 4. Schering-Plough had sought approval for ...